R-CHOP is found to be more effective than ABVD in non-Hodgkin lymphoma, as well as in advanced NLPHL, especially regarding the 10-year recurrence [10–12]; therefore, the patient was switched early to R-CHOP after immunostaining confirmed the presence of two types of lymphoma. Here, DDIT3 is linked to non-Hodgkin lymphoma.